← Back to Index

Clinical Decision Support

Bayesian Vancomycin
PK Calculator

An advanced pharmacokinetic calculator implementing Bayesian Maximum A Posteriori (MAP) estimation for individualized vancomycin dosing. Supports multiple validated population PK models, AUC-guided dosing per ASHP/IDSA 2020 consensus guidelines, and real-time concentration-time profiling.

5 Population PK ModelsBayesian MAP EstimationAUC/MIC TargetingCockcroft-Gault CrClAllometric ScalingOne-Compartment IV InfusionMulti-Dose SuperpositionInteractive PK Curves

Methodology: Five published population PK models with Bayesian MAP estimation. AUC-guided dosing per ASHP/IDSA/SIDP 2020 consensus guidelines. All calculations run client-side with no patient data transmitted.

01

Patient Demographics

Calculated Values
CrCl
82.6mL/min
IBW
65.9kg
ABW
67.6kg
Status
Normal
02

Population PK Model

Select PK Model
03

Dosing & Targets

Current Dosing

Targets

04

Observed Drug Levels (Bayesian Updating)

Enter measured vancomycin serum levels to refine PK estimates via Bayesian MAP estimation. The algorithm updates population priors with patient-specific data to generate individualized parameters.

Observed Levels

No observed levels entered

Add drug levels to enable Bayesian parameter estimation

05

Estimated PK Parameters

Population Estimate
CL (L/hr)
7.183
Vd (L)
49.70
ke (hr¹)
0.1445
Half-life (hr)
4.8
06

Concentration-Time Profile

Concentration-Time Profile (72 hr)

Blue line: predicted concentration curve | Red dots: observed levels | Green band: target trough range

07

Dose Recommendations

Dose (mg)IntervalPred PeakPred TroughAUC₂₄/MICRationale
1750Recommended
q12h40.9 mg/L8.1 mg/L487AUC₂₄/MIC 487 within target 400-600
1250
q8h35.8 mg/L12.4 mg/L522AUC₂₄/MIC 522 within target 400-600
2000
q12h46.7 mg/L9.3 mg/L557AUC₂₄/MIC 557 within target 400-600
1000
q8h28.7 mg/L9.9 mg/L418AUC₂₄/MIC 418 within target 400-600
1500
q12h35.1 mg/L7.0 mg/L418AUC₂₄/MIC 418 within target 400-600

Technical Architecture

Bayesian MAP

Grid-search optimization minimizing the MAP objective function with log-normal priors. Two-phase approach: coarse grid (30×20) followed by fine refinement (20×20) around the optimum.

PK Engine

One-compartment IV infusion model with multi-dose superposition. Steady-state peak/trough via accumulation factor. AUC₂₄ calculated both analytically (Dose₂₄/CL) and via trapezoidal integration.

Population Models

Five validated models spanning 1984-2018: Matzke, Bauer, Thomson, Crass, and Empiric Trough. Each provides population priors for CL and Vd with inter-individual variability (BSV) estimates.

References

  • Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: ASHP/IDSA/SIDP 2020 Update. Am J Health-Syst Pharm. 2020;77(11):835-864.
  • Crass RL, et al. Renal dosing of vancomycin. Clin Infect Dis. 2020;71(6):1560-1567.
  • Thomson AH, et al. Development and evaluation of vancomycin dosage guidelines. J Antimicrob Chemother. 2009;63(5):1050-1057.
  • Bauer LA. Applied Clinical Pharmacokinetics. 2nd ed. McGraw-Hill; 2008.
  • Matzke GR, et al. Clinical pharmacokinetics of vancomycin. Antimicrob Agents Chemother. 1984;25(4):433-437.

Daniel Tran, PharmD

UC San Diego — Skaggs School of Pharmacy

Source code MIT. Content © 2026 Daniel Tran (CC BY-NC-SA 4.0).